Arvinas Announces Changes to its Board of Directors
18 août 2022 16h01 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041
17 août 2022 12h38 HE
|
Trethera Corporation
LOS ANGELES, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Precipio Launches New 1-Step Technology for all HemeScreen Assays
16 août 2022 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s...
Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe
16 août 2022 01h05 HE
|
Myriad Genetics, Inc.
Collaboration brings MyChoice CDx Plus Testing to Hamburg, Germany and Dijon, FranceLatest expansions represent Myriad’s commitment to growing international lab partner program SALT LAKE CITY, Aug....
Oncology Cancer Drugs Market Size is projected to reach USD 288 Billion by 2030, growing at a CAGR of 7.7%: Straits Research
15 août 2022 15h50 HE
|
Straits Research
New York, United States, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cancer develops when the body's common control mechanism malfunctions and cannot stop the proliferation of abnormal cells. In this case,...
Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
15 août 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
15 août 2022 01h15 HE
|
Novartis Pharma AG
Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be presented at...
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
12 août 2022 08h30 HE
|
POINT Biopharma
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters...
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
11 août 2022 16h15 HE
|
Aprea Therapeutics
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
11 août 2022 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...